Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Rating) – Stock analysts at Oppenheimer increased their FY2026 earnings estimates for Viracta Therapeutics in a research note issued to investors on Wednesday, November 16th. Oppenheimer analyst H. Singh now forecasts that the company will post earnings of $2.49 per share for the year, up from their prior forecast of $2.47. The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($1.31) per share.
Separately, Royal Bank of Canada dropped their price target on shares of Viracta Therapeutics from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Friday, November 11th.
Viracta Therapeutics Stock Performance
Viracta Therapeutics (NASDAQ:VIRX – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.16).
Insiders Place Their Bets
In other Viracta Therapeutics news, CEO Ivor Royston sold 13,379 shares of the company’s stock in a transaction on Friday, August 26th. The shares were sold at an average price of $4.01, for a total value of $53,649.79. Following the transaction, the chief executive officer now directly owns 612,770 shares in the company, valued at $2,457,207.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 19,224 shares of company stock valued at $77,125. 27.63% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Viracta Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. Veritable L.P. acquired a new position in shares of Viracta Therapeutics in the first quarter valued at $118,000. Clear Harbor Asset Management LLC acquired a new position in shares of Viracta Therapeutics in the second quarter valued at $97,000. MAI Capital Management increased its holdings in shares of Viracta Therapeutics by 70.2% in the second quarter. MAI Capital Management now owns 647,950 shares of the company’s stock valued at $2,514,000 after purchasing an additional 267,162 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Viracta Therapeutics in the second quarter valued at $1,227,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Viracta Therapeutics by 35.5% in the second quarter. Goldman Sachs Group Inc. now owns 204,164 shares of the company’s stock valued at $792,000 after purchasing an additional 53,475 shares during the last quarter. 30.36% of the stock is currently owned by institutional investors and hedge funds.
About Viracta Therapeutics
Viracta Therapeutics, Inc, a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
- Get a free copy of the StockNews.com research report on Viracta Therapeutics (VIRX)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.